Author Affiliation: Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Md.
Quite simply, the Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) is one of the most important trials of antihypertensive
therapy. For decades, experts have passionately debated which class of drugs
should be initial therapy for hypertension. Resolution of this issue, which
has enormous clinical, public health, and economic implications, comes at
a time of intense pressure to reduce health care costs while improving clinical
outcomes. In this setting, the ALLHAT results, reported in this issue of THE
JOURNAL, are particularly noteworthy, because there is no cost-quality tradeoff;
the most effective therapy was also the least expensive.1
Appel LJ. The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension. JAMA. 2002;288(23):3039–3042. doi:10.1001/jama.288.23.3039
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: